Researchers are exploring ways to overcome chemoresistance in ovarian cancer, with one approach involving the co-delivery of cisplatin and siRNA via nanocapsules. Other methods being investigated include the use of nanoparticles to co-deliver different siRNAs, such as MDR1 and BCL2, to overcome resistance to certain chemotherapy drugs. The mechanisms of cisplatin resistance in ovarian cancer cells are also being studied, with potential involvement of various signaling pathways.